Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors


You May Also Like

RedHill Biopharma to Present at the 18th Annual BIO CEO & Investor Conference

TEL-AVIV, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...

MacroGenics Announces Five Posters at AACR Annual Meeting 2016

ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage ...